Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study

被引：91
|
作者：
Qin, Shukui
Chen, Zhendong
Fang, Weijia
Ren, Zhenggang
Xu, Ruocai
Ryoo, Baek-Yeol
Meng, Zhiqiang
Bai, Yuxian
Chen, Xiaoming
Liu, Xiufeng
Xiao, Juxiang
Ho, Gwo Fuang
Mao, Yimin
Ye, Xing
Ying, Jieer
Li, Jianfeng
Zhong, Wen Yan
Zhou, Yu
Siegel, Abby B.
Hao, Chunyi
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Ctr Canc, Nanjing, Peoples R China
[2] Anhui Med Univ, Hosp 2, Hefei, Peoples R China
[3] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[9] Guangdong Prov Peoples Hosp, Dept Intervent Radiol, Guangzhou, Peoples R China
[10] Chinese PLA, Eastern Theater Gen Hosp, Nanjing, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaaxi, Peoples R China
[12] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[13] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China
[14] Deyang Hosp, Deyang, Peoples R China
[15] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China
[16] MSD China, Beijing, Peoples R China
[17] MSD China, Shanghai, Peoples R China
[18] Columbia Univ, New York, NY USA
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
383
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup
    Kudo, Masatoshi
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Chao, Yee
    Yau, Thomas
    Ogasawara, Sadahisa
    Kurosaki, Masayuki
    Morimoto, Naoki
    Ohkawa, Kazuyoshi
    Yamashita, Tatsuya
    Lee, Kyung-Hun
    Chen, Erluo
    Siegel, Abby B.
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [12] Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
    Finn, R. S.
    Ryoo, B-Y
    Merle, P.
    Kudo, M.
    Bouattour, M.
    Lim, H-Y
    Breder, V.
    Edeline, J.
    Chao, Y.
    Ogasawara, S.
    Yau, T.
    Garrido, M.
    Chan, S. L.
    Knox, J.
    Daniele, B.
    Ebbinghaus, S. W.
    Chen, E.
    Siegel, A. B.
    Zhu, A. X.
    Cheng, A-L
    ANNALS OF ONCOLOGY, 2019, 30
  • [13] Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
    Andrea Casadei Gardini
    Flavia Foca
    Mario Scartozzi
    Nicola Silvestris
    Emiliano Tamburini
    Luca Faloppi
    Oronzo Brunetti
    Britt Rudnas
    Salvatore Pisconti
    Martina Valgiusti
    Giorgia Marisi
    Francesco Giuseppe Foschi
    Giorgio Ercolani
    Davide Tassinari
    Stefano Cascinu
    Giovanni Luca Frassineti
    Scientific Reports, 7
  • [14] Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
    Gardini, Andrea Casadei
    Foca, Flavia
    Scartozzi, Mario
    Silvestris, Nicola
    Tamburini, Emiliano
    Faloppi, Luca
    Brunetti, Oronzo
    Rudnas, Britt
    Pisconti, Salvatore
    Valgiusti, Martina
    Marisi, Giorgia
    Foschi, Francesco Giuseppe
    Ercolani, Giorgio
    Tassinari, Davide
    Cascinu, Stefano
    Frassineti, Giovanni Luca
    SCIENTIFIC REPORTS, 2017, 7
  • [15] Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
    Ciuleanu, T. E.
    Brodowicz, T.
    Belani, C. P.
    Kim, J.
    Krzakowski, M.
    Laack, E.
    Wu, Y.
    Peterson, P.
    Adachi, S.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu, Tudor
    Brodowicz, Thomas
    Zielinski, Christoph
    Kim, Joo Hang
    Krzakowski, Maciej
    Laack, Eckart
    Wu, Yi-Long
    Bover, Isabel
    Begbie, Stephen
    Tzekova, Valentina
    Cucevic, Branka
    Pereira, Jose Rodrigues
    Yang, Sung Hyun
    Madhavan, Jayaprakash
    Sugarman, Katherine P.
    Peterson, Patrick
    John, William J.
    Krejcy, Kurt
    Belani, Chandra P.
    LANCET, 2009, 374 (9699): : 1432 - 1440
  • [17] Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    Li, Jin
    Qin, Shukui
    Xu, Ruihua
    Yau, Thomas C. C.
    Ma, Brigette
    Pan, Hongming
    Xu, Jianming
    Bai, Yuxian
    Chi, Yihebali
    Wang, Liwei
    Yeh, Kun-Huei
    Bi, Feng
    Cheng, Ying
    Le, Anh Tuan
    Lin, Jen-Kou
    Liu, Tianshu
    Ma, Dong
    Kappeler, Christian
    Kalmus, Joachim
    Kim, Tae Won
    LANCET ONCOLOGY, 2015, 16 (06): : 619 - 629
  • [18] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
    Jassem, Jacek
    Ramlau, Rodryg
    Santoro, Armando
    Schuette, Wolfgang
    Chemaissani, Assad
    Hong, Shengyan
    Blatter, Johannes
    Adachi, Susumu
    Hanauske, Axel
    Manegold, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1698 - 1704
  • [19] Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
    Xie, Qian
    Zheng, Hanrui
    Chen, Ye
    Peng, Xingchen
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [20] A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
    Su, Po-Jung
    Xiao, Ying
    Lin, Amy Y.
    Goh, Connie
    Wu, Ethan
    Liu, Kevin
    Chou, Patrick
    Kuo, Kaitlin
    Palencia, Roberto
    Chang, Jane
    Kearney, Mairead
    Kapetanakis, Venediktos
    Benedict, Agnes
    CANCER REPORTS, 2023,
12345